BACKGROUND AND OBJECTIVES: The extent to which hemoglobin (Hb) cycling occurs in peritoneal dialysis (PD) patients is unclear. It is also uncertain whether different types of erythropoiesis-stimulating agents (ESAs) affect such cycling. We performed a retrospective cohort study of our PD population before and after the entire program was switched from epoetin beta (NeoRecormon: Hoffman-LaRoche, Basel, Switzerland) to continuous erythropoietin receptor activator [CERA (Mircera: Hoffman-LaRoche)]. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: The study included 79 patients receiving PD for end-stage renal failure and being treated with an ESA. Hemoglobin concentrations were measured monthly, and each study period ran for 12 months. Patient demographics and details of intercurrent illness and hospital admission were collected. RESULTS: There was a trend to fewer patients on CERA (26 patients, 68.4%) than on epoetin beta (36 patients, 87.8%, p = 0.054) experiencing Hb excursions. The CERA group also required fewer dose changes. However, there was no difference in the proportion of patients experiencing complete Hb cycles. On logistic regression, the factors associated with Hb cycling were ESA dose increase or decrease and hospital admission. We also observed a positive correlation between the delta ESA dose and the amplitude of Hb excursion, suggesting that the dose changes were causal, rather than reactive. CONCLUSIONS: Hemoglobin cycling occurs in PD patients and is largely a consequence of current practice in ESA dosing, plus the effects of intercurrent illness. The longer half life of CERA may offer a small advantage in reducing the degree of Hb variability, possibly because of fewer dose changes per patient.
BACKGROUND AND OBJECTIVES: The extent to which hemoglobin (Hb) cycling occurs in peritoneal dialysis (PD) patients is unclear. It is also uncertain whether different types of erythropoiesis-stimulating agents (ESAs) affect such cycling. We performed a retrospective cohort study of our PD population before and after the entire program was switched from epoetin beta (NeoRecormon: Hoffman-LaRoche, Basel, Switzerland) to continuous erythropoietin receptor activator [CERA (Mircera: Hoffman-LaRoche)]. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: The study included 79 patients receiving PD for end-stage renal failure and being treated with an ESA. Hemoglobin concentrations were measured monthly, and each study period ran for 12 months. Patient demographics and details of intercurrent illness and hospital admission were collected. RESULTS: There was a trend to fewer patients on CERA (26 patients, 68.4%) than on epoetin beta (36 patients, 87.8%, p = 0.054) experiencing Hb excursions. The CERA group also required fewer dose changes. However, there was no difference in the proportion of patients experiencing complete Hb cycles. On logistic regression, the factors associated with Hb cycling were ESA dose increase or decrease and hospital admission. We also observed a positive correlation between the delta ESA dose and the amplitude of Hb excursion, suggesting that the dose changes were causal, rather than reactive. CONCLUSIONS: Hemoglobin cycling occurs in PDpatients and is largely a consequence of current practice in ESA dosing, plus the effects of intercurrent illness. The longer half life of CERA may offer a small advantage in reducing the degree of Hb variability, possibly because of fewer dose changes per patient.
Authors: Karien van der Putten; Frederieke H van der Baan; Huub Schellekens; Carlo A J M Gaillard Journal: Int J Artif Organs Date: 2009-11 Impact factor: 1.595
Authors: Samer S Najjar; Sunil V Rao; Chiara Melloni; Subha V Raman; Thomas J Povsic; Laura Melton; Gregory W Barsness; Kristi Prather; John F Heitner; Rakhi Kilaru; Luis Gruberg; Vic Hasselblad; Adam B Greenbaum; Manesh Patel; Raymond J Kim; Mark Talan; Luigi Ferrucci; Dan L Longo; Edward G Lakatta; Robert A Harrington Journal: JAMA Date: 2011-05-11 Impact factor: 56.272
Authors: Bruce Spinowitz; Daniel W Coyne; Charmaine E Lok; Mario Fraticelli; Maher Azer; Sanjay Dalal; Giuseppe Villa; Steven Rosansky; Helena Adamis; Ulrich Beyer Journal: Am J Nephrol Date: 2007-11-13 Impact factor: 3.754
Authors: Areef Ishani; Craig A Solid; Eric D Weinhandl; David T Gilbertson; Robert N Foley; Allan J Collins Journal: Nephrol Dial Transplant Date: 2007-12-08 Impact factor: 5.992
Authors: Steven M Brunelli; Marshall M Joffe; Rubeen K Israni; Wei Yang; Steven Fishbane; Jeffrey S Berns; Harold I Feldman Journal: Clin J Am Soc Nephrol Date: 2008-03-12 Impact factor: 8.237
Authors: Anatole Besarab; Moro O Salifu; N Martin Lunde; Vinod Bansal; Steven Fishbane; Frank C Dougherty; Ulrich Beyer Journal: Clin Ther Date: 2007-04 Impact factor: 3.393
Authors: David T Gilbertson; James P Ebben; Robert N Foley; Eric D Weinhandl; Brian D Bradbury; Allan J Collins Journal: Clin J Am Soc Nephrol Date: 2007-11-28 Impact factor: 8.237
Authors: A Vega; S Abad; U Verdalles; I Aragoncillo; K Velazquez; B Quiroga; V Escudero; J M López-Gómez Journal: Hippokratia Date: 2014 Oct-Dec Impact factor: 0.471